Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T17:32:48.804Z.
Calculation as of: 2026-10-06T17:32:48.804Z.
Quote observation: 2026-10-06T17:30:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 820e6844a86ebcce87b4cbc727545bf8fd5f2e7882f78b89935f6b0fc3bd738c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Larimar Therapeutics, Inc.
Market Cap
$290.35M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$289.84M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$285.42M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$285.02M
Operating Cash Flow Yield
N/A
TTM Avg
41.23%
3Y Avg
41.23%
5Y Avg
41.23%
Market Cap
$283.55M
Operating Cash Flow Yield
N/A
TTM Avg
1.81%
3Y Avg
1.81%
5Y Avg
1.81%
Market Cap
$280.78M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$281.16M
Operating Cash Flow Yield
N/A
TTM Avg
1.84%
3Y Avg
1.84%
5Y Avg
1.84%
Market Cap
$302.14M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$279.67M
Operating Cash Flow Yield
N/A
TTM Avg
2.67%
3Y Avg
2.67%
5Y Avg
2.67%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Larimar Therapeutics, Inc. (LRMR) | $290.35M | N/A | N/A | N/A | N/A |
| Standard BioTools Inc. (LAB)vs › | $289.84M | N/A | N/A | N/A | N/A |
| Sagimet Biosciences Inc. (SGMT)vs › | $285.42M | N/A | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $285.02M | N/A | 41.23% | 41.23% | 41.23% |
| Abeona Therapeutics Inc. (ABEO)vs › | $283.55M | N/A | 1.81% | 1.81% | 1.81% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $280.78M | N/A | N/A | N/A | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.16M | N/A | 1.84% | 1.84% | 1.84% |
| Benitec Biopharma Inc. (BNTC)vs › | $302.14M | N/A | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $279.67M | N/A | 2.67% | 2.67% | 2.67% |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $303.13M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
